This site is intended for healthcare professionals

FDA approval of Oxlumo, the first and only treatment approved for primary hyperoxaluria type 1 to lower urinary oxalate levels in pediatric and adult patients. - Alnylam Pharma.

Read time: 1 mins
Last updated:25th Nov 2020
Published:25th Nov 2020
Condition: Hyperoxaluria
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest